Humanized mouse G6 anti-idiotypic monoclonal antibody has therapeutic potential against IGHV1-69 germline gene-based B-CLL

ABSTRACT In 10–20% of the cases of chronic lymphocytic leukemia of B-cell phenotype (B-CLL), the IGHV1-69 germline is utilized as VH gene of the B cell receptor (BCR). Mouse G6 (MuG6) is an anti-idiotypic monoclonal antibody discovered in a screen against rheumatoid factors (RFs) that binds with high affinity to an idiotope expressed on the 51p1 alleles of IGHV1-69 germline gene encoded antibodies (G6-id+). The finding that unmutated IGHV1-69 encoded BCRs are frequently expressed on B-CLL cells provides an opportunity for anti-idiotype monoclonal antibody immunotherapy. In this study, we first showed that MuG6 can deplete B cells encoding IGHV1-69 BCRs using a novel humanized GTL mouse model. Next, we humanized MuG6 and demonstrated that the humanized antibodies (HuG6s), especially HuG6.3, displayed ∼2-fold higher binding affinity for G6-id+ antibody compared to the parental MuG6. Additional studies showed that HuG6.3 was able to kill G6-id+ BCR expressing cells and patient B-CLL cells through antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Finally, both MuG6 and HuG6.3 mediate in vivo depletion of B-CLL cells in NSG mice. These data suggest that HuG6.3 may provide a new precision medicine to selectively kill IGHV1-69-encoding G6-id+ B-CLL cells.

[1]  N. Chiorazzi,et al.  Murine genetically engineered and human xenograft models of chronic lymphocytic leukemia. , 2014, Seminars in hematology.

[2]  Ash A. Alizadeh,et al.  Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  G. Simonetti,et al.  Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions , 2013, Leukemia.

[4]  James J. Campbell,et al.  Human Anti-CCR4 Minibody Gene Transfer for the Treatment of Cutaneous T-Cell Lymphoma , 2012, PloS one.

[5]  James J. Campbell,et al.  Humanization of an Anti-CCR4 Antibody That Kills Cutaneous T-Cell Lymphoma Cells and Abrogates Suppression by T-Regulatory Cells , 2012, Molecular Cancer Therapeutics.

[6]  P. T. N. Sarkis,et al.  Human B-cell ontogeny in humanized NOD/SCID γcnull mice generates a diverse yet auto/poly- and HIV-1 reactive antibody repertoire , 2012, Genes and Immunity.

[7]  M. Hallek,et al.  Action of novel CD37 antibodies on chronic lymphocytic leukemia cells , 2012, Leukemia.

[8]  J. Haidar,et al.  A universal combinatorial design of antibody framework to graft distinct CDR sequences: A bioinformatics approach , 2012, Proteins.

[9]  C. Stoddart,et al.  Alpha Interferon and HIV Infection Cause Activation of Human T Cells in NSG-BLT Mice , 2012, Journal of Virology.

[10]  P. T. N. Sarkis,et al.  Humoral immune responses in humanized BLT mice immunized with West Nile virus and HIV‐1 envelope proteins are largely mediated via human CD5+ B cells , 2011, Immunology.

[11]  D. Castellano,et al.  Therapeutic management of chronic lymphocytic leukaemia: state of the art and future perspectives. , 2011, Critical reviews in oncology/hematology.

[12]  H. Nückel,et al.  Investigating the role of CD38 and functionally related molecular risk factors in the CLL NOD/SCID xenograft model , 2011, European journal of haematology.

[13]  Annette Lee,et al.  A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. , 2011, Blood.

[14]  G. Marti,et al.  Immnuophenotypic and Gene Expression Analysis of Monoclonal B Cell Lymphocytosis Shows Biologic Characteristics Associated With Good Prognosis CLL , 2011, Leukemia.

[15]  M. Lanasa.  Novel insights into the biology of CLL. , 2010, Hematology. American Society of Hematology. Education Program.

[16]  R. Kunert,et al.  Humanization strategies for an anti-idiotypic antibody mimicking HIV-1 gp41. , 2010, Protein engineering, design & selection : PEDS.

[17]  M. Ott,et al.  Generation of Human Antigen-Specific Monoclonal IgM Antibodies Using Vaccinated “Human Immune System” Mice , 2010, PloS one.

[18]  M. Egholm,et al.  Individual Variation in the Germline Ig Gene Repertoire Inferred from Variable Region Gene Rearrangements , 2010, The Journal of Immunology.

[19]  T. Lin.  New Agents in Chronic Lymphocytic Leukemia , 2010, Current hematologic malignancy reports.

[20]  K. Stamatopoulos,et al.  The normal IGHV1-69-derived B-cell repertoire contains stereotypic patterns characteristic of unmutated CLL. , 2009, Blood.

[21]  F. Marincola,et al.  Patients Treated with Rituximab-Containing Immunochemotherapy Have a Significant and Prolonged Lack of Humoral Response to Influenza Vaccine Associated with a Persistent Depletion of B Memory Cells. , 2009 .

[22]  J. Gribben,et al.  Dramatic Reduction of Chronic Lymphocytic Leukemia (CLL) Cells Following Adoptive Transfer of Cord Blood (CB) Natural Killer (NK) Cells Using CB-Engrafted NOD-SCID IL2Rγ null (NSG) Mice as a Model. , 2009 .

[23]  J. Voorberg,et al.  VH1‐69 germline encoded antibodies directed towards ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura , 2009, Journal of thrombosis and haemostasis : JTH.

[24]  D. Aird,et al.  Lentivirus Display: Stable Expression of Human Antibodies on the Surface of Human Cells and Virus Particles , 2008, PLoS ONE.

[25]  Michael Hallek,et al.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.

[26]  R. Chiaraluce,et al.  Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting. , 2008, Molecular immunology.

[27]  Nikolaos Laoutaris,et al.  Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. , 2007, Blood.

[28]  J. Dürig,et al.  A novel nonobese diabetic/severe combined immunodeficient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the disease. , 2007, Cancer research.

[29]  Patrice Cacoub,et al.  The pathophysiology of HCV induced B-cell clonal disorders. , 2007, Autoimmunity reviews.

[30]  Thomas S. Lin,et al.  Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. , 2007, Blood.

[31]  Nikolaos Laoutaris,et al.  Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. , 2006, Blood.

[32]  J. C. Almagro,et al.  Use of human germline genes in a CDR homology-based approach to antibody humanization. , 2005, Methods.

[33]  Nikolaos Laoutaris,et al.  Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. , 2005, Blood.

[34]  J. Gribben,et al.  Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. , 2004, Blood.

[35]  M. Grever,et al.  A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. , 2004, Blood.

[36]  Steven L. Allen,et al.  Multiple Distinct Sets of Stereotyped Antigen Receptors Indicate a Role for Antigen in Promoting Chronic Lymphocytic Leukemia , 2004, The Journal of experimental medicine.

[37]  N. Chiorazzi,et al.  The pattern and distribution of immunoglobulin VH gene mutations in chronic lymphocytic leukemia B cells are consistent with the canonical somatic hypermutation process. , 2004, Blood.

[38]  Wenhui Li,et al.  Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[39]  H. Kantarjian,et al.  Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. , 2003, Blood.

[40]  P. Richardson,et al.  Recombinant humanized anti‐CD40 monoclonal antibody triggers autologous antibody‐dependent cell‐mediated cytotoxicity against multiple myeloma cells , 2003, British journal of haematology.

[41]  J. Orchard,et al.  Features of the overexpressed V1-69 genes in the unmutated subset of chronic lymphocytic leukemia are distinct from those in the healthy elderly repertoire. , 2003, Blood.

[42]  D. Czerwinski,et al.  Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. , 2002, Blood.

[43]  T. Robak.  The Role of Nucleoside Analogues in the Treatment of Chronic Lymphocytic Leukemia-Lessons Learned from Prospective Randomized Trials , 2002, Leukemia & lymphoma.

[44]  P. Parren,et al.  Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1 , 2001, Journal of Virology.

[45]  T. Barbui,et al.  CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. , 2001, Blood.

[46]  R. Marasca,et al.  Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma. , 2001, The American journal of pathology.

[47]  M. Grever,et al.  Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  G. Widhopf,et al.  Normal B Cells Express 51p1-Encoded Ig Heavy Chains That Are Distinct From Those Expressed by Chronic Lymphocytic Leukemia B Cells1 , 2001, The Journal of Immunology.

[49]  A R Rees,et al.  WAM: an improved algorithm for modelling antibodies on the WEB. , 2000, Protein engineering.

[50]  U Stocker,et al.  Molecular dynamics simulation of hen egg white lysozyme: A test of the GROMOS96 force field against nuclear magnetic resonance data , 2000, Proteins.

[51]  N. Chiorazzi,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.

[52]  T J Hamblin,et al.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.

[53]  Capra,et al.  Molecular Characterization of the VH1‐Specific Variable Region Determinants Recognized by Anti‐Idiotypic Monoclonal Antibodies G6 and G8 , 1999, Scandinavian journal of immunology.

[54]  L. Rassenti,et al.  Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. , 1998, The Journal of clinical investigation.

[55]  R. Brezinschek,et al.  Similar characteristics of the CDR3 of VH1‐69/DP‐10 rearrangements in normal human peripheral blood and chronic lymphocytic leukaemia B cells , 1998, British journal of haematology.

[56]  O. Burrone,et al.  Somatic hypermutation, clonal diversity, and preferential expression of the VH 51p1/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas. , 1998, Blood.

[57]  Leonard,et al.  Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.

[58]  O. Tapia,et al.  On the sensitivity of MD trajectories to changes in water‐protein interaction parameters: The potato carboxypeptidase inhibitor in water as a test case for the GROMOS force field , 1996, Proteins.

[59]  D. Greiner,et al.  Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. , 1995, Journal of immunology.

[60]  P. Chinn,et al.  Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. , 1994, Blood.

[61]  L. Presta,et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[62]  A. George,et al.  Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1. , 1987, Journal of immunology.

[63]  M. Karplus,et al.  Prediction of the folding of short polypeptide segments by uniform conformational sampling , 1987, Biopolymers.

[64]  G. Hale,et al.  Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. , 1983, Blood.

[65]  Jeffrey A Jones,et al.  Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals , 2010 .

[66]  K. Stamatopoulos,et al.  A different ontogenesis for chronic lymphocytic leukemia cases carrying stereotyped antigen receptors: molecular and computational evidence , 2010, Leukemia.

[67]  R. Jefferis,et al.  Immunogenic and antigenic epitopes of immunoglobulins XVII-monoclonal antibodies reactive with common and restricted idiotopes to the heavy chain of human rheumatoid factors , 2004, Rheumatology International.

[68]  N. Guex,et al.  SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling , 1997, Electrophoresis.

[69]  D. Osguthorpe,et al.  Structure and energetics of ligand binding to proteins: Escherichia coli dihydrofolate reductase‐trimethoprim, a drug‐receptor system , 1988, Proteins.

[70]  P. T. Jones,et al.  Replacing the complementarity-determining regions in a human antibody with those from a mouse , 1986, Nature.